r-18

Antagonist of 14.3.3 proteins (KD ≈80 nM). Competitively inhibits 14.3.3-ligand interactions without requiring phosphorylation. Blocks the ability of 14.3.3 to bind to target proteins such as Raf-1, Bad, ASK1 and exoenzyme S.

R18 TFA, a peptide antagonist of 14-3-3, exhibits a dissociation constant (K_D) of 70-90 nM. It efficiently inhibits the interaction between 14-3-3 and its physiological ligand, the kinase Raf-1, thereby significantly impeding the protective effect of 14-3-3 on Raf-1 against phosphatase-induced deactivation [1].

OR-1896 is the active metabolite of Levosimendan, a highly specific phosphodiesterase (PDE III) inhibitor, a vasodilator with partial anti-inflammatory properties that produces vasodilation in different types of blood vessels through activation of ATP-sensitive (KATP) and other potassium channels.OR-1896 can be used to study heart failure and vascular dysfunction. OR-1896 can be used to study heart failure and vascular dysfunction.

OR-1855 is an active Levosimendan metabolite, has effect on human myometrial contractility.

FR-188582 is a highly selective cyclooxygenase (COX)-2 inhibitor [IC50: 17 nM].

Bayer-18 is an inhibitor of TYK2. It inhibits the viability of anaplastic large cell lymphoma cells, including K299, SR786, Mac1, and Mac2a, with an IC50 ranging from 2-3 µM. Additionally, Bayer-18 induces apoptosis in K299 and SR786 cells.

PROTAC SMARCA2 degrader-18 (Example144) is a PROTAC SMARCA2 degrader with potential for researching non-small cell lung cancer (NSCLC).

FGFR1 inhibitor-18 (compound 16) is a potent inhibitor of FGFR1 with an IC50 of 1.31 nM. It effectively occupies the ATP binding site of the target FGFR1.

SR-1815 is a small-molecule multi-kinase inhibitor. By regulating mechanisms such as splicing, SR-1815 effectively restores SynGAP protein to normal levels in disease models with Syngap1 haploinsufficiency, correcting synaptic and neuronal network functional abnormalities caused by the gene defect. SR-1815 is used for research into brain disorders.

FR-181157, a novel prostaglandin (PG) mimetic, shows high potency and agonist efficacy at the IP receptor and has good bioavailability.

FR-181877, a nonprostanoid PGI2 agonist, inhibits ADP-induced aggregation of human platelets with an IC50 value of 0.081 microM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats.

FR-182024 is a novel cephem derivative, it has potent anti-Helicobacter pylori activity.

FR-186054 is a new, potent inhibitor of acyl-CoA:cholesterol O-acyltransferase (ACAT) and has oral activity. Compared to other ACAT inhibitors, this compound displayed excellent in vitro efficacy, irrespective of dosing method, indicating superior charact

R-18893, a RNA-directed DNA polymerase inhibitor, is used potentially for the treatment of HIV-1 infection.

SSR-182289A (Free) is a thrombin inhibitor.

FR-182980 is a bio-active chemical. Detailed information has not been published.

SR-18292 is an inhibitor of PPAR gamma coactivator-1α (PGC-1α), which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.

KRAS inhibitor-18 (compound 3-10) is a potent inhibitor of KRAS G12C (IC50: 4.74 μM) and exhibited p-ERK inhibition in MIA PaCA-2 and A549 cells with IC50s of 66.4 μM and 11.1 μM, respectively. KRAS inhibitor-18 has potential for pancreatic, colorectal, and lung cancer studies.

BRD4 Inhibitor-18 is a potent BRD4 inhibitor (IC50: 110 nM) with a hydrophobic acetylcyclopentane side chain. BRD4 Inhibitor-18 significantly reduces the proliferation of MV-4-11 cells with high BRD4 levels, inhibits G0/G1 cycle activity, and promotes apoptosis. The inhibition of G0/G1 cycle activity and apoptosis were also observed.

HIV-1 inhibitor-18 is a potent inhibitor of the HIV-1 capsid that acts against the HIV-1 NL4-3 strain (EC50: 5.14 μM) and exhibits some cytotoxicity (MT-4CC50>9.51).

Water-18O is a useful organic compound for research related to life sciences and the catalog number is T64656.

THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.

PROTAC SMARCA2/4-degrader-18 (Compound I-348) is a PROTAC degrader targeting the catalytic subunits SMARCA2 and SMARCA4 of the SWI/SNF complex. It effectively degrades SMARCA2 in A549 cells with a DC50 value of less than 100 nM and similarly degrades SMARCA4 in MV411 cells, also with a DC50 of less than 100 nM.

OR-1896-d3 is the deuterium-labeled form of OR-1896, which is the active, long-lasting metabolite of Levosimendan. It acts as a highly selective phosphodiesterase (PDE III) inhibitor and serves as a potent vasodilator. OR-1896 is capable of opening ATP-sensitive K+ channels and demonstrates Ca2+ sensitizing effects, which help reduce apoptosis in myocardial cells, cardiac remodeling, and myocardial inflammation.